Esprit™ BTK 生体吸収過程

スキャフォールドが血管に留置され、薬剤が徐放された後、スキャフォールドは経時的に分解され、スキャフォールドマーカーを除いて生体吸収される ^{1 *}

Absorb™ BVS を留置したブタ冠動脈の代表的な顕微鏡写真（ 12 ～ 48ヶ月）

* プラチナ製マーカーを除く

References

1. Data on file at Abbott.
2. Esprit™ BTK Everolimus Eluting Resorbable Scaffold System Instructions for Use (IFU).
3. Data on file at Abbott. Testing done with XIENCE Sierra™ 3.5 x 38 mm at nominal.
4. Brian G. DeRubertis et al., Two-Year Outcomes of the LIFE-BTK Randomized Controlled Trial Evaluating the Esprit™ BTK Drug-eluting Resorbable Scaffold for Treatment of Infrapopliteal Lesions, VIVA 2024.
5. Superiority analysis was performed at 1 year.
6. By Newcombe score method.
7. Varcoe, R., Primary Outcomes of the Esprit™ BTK Drug-Eluting Resorbable Scaffold for the Treatment of Infrapopliteal Lesions: The LIFE-BTK Trial. Presented at TCT 2023.
8. Reintervention defined as CD-TLR.